Liquid formulation of long acting insulinotropic peptide conjugate
Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
1. A liquid formulation of a long-acting insulinotropic peptide conjugate, comprising:
a pharmaceutically effective amount of the long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide is linked to an immunoglobulin Fc region; and
an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant,
wherein the insulinotropic peptide is glucagon-like peptide-1, glucagon-like peptide-2, exendin-3, exendin-4, or imidazo-acetyl exendin-4;
wherein the formulation has a pH of about 5.2 to about 7.0; and
wherein the non-ionic surfactant has a concentration of about 0.001% (w/v) to about 0.05% (w/v).
2. The liquid formulation according to claim 1 , wherein the immunoglobulin Fc region is an Fc region derived from IgG, IgA, IgD, IgE, or IgM.
3. The liquid formulation according to claim 2 , wherein the immunoglobulin Fc region is a hybrid of domains of different origins derived from immunoglobulins selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.
4. The liquid formulation according to claim 2 , wherein the immunoglobulin Fc region is a dimer or multimer consisting of single-chain immunoglobulins composed of domains of the same origin.
5. The liquid formulation of according to claim 2 , wherein the immunoglobulin Fc region is an IgG4 Fc region.
6. The liquid formulation according to claim 5 , wherein the immunoglobulin Fc region is a human aglycosylated IgG4 Fc region.
7. The liquid formulation according to claim 1 , wherein the insulinotropic peptide is linked to the immunoglobulin Fc region via a non-peptidyl polymer or a fusion protein.
8. The liquid formulation according to claim 7 , wherein the non-peptidyl polymer is a polyethylene glycol.
9. The liquid formulation according to claim 7 , wherein the non-peptidyl polymer is selected from the group consisting of a biodegradable polymer; a lipid polymer; chitins; hyaluronic acid; and a combination thereof, wherein said biodegradable polymer is selected from the group consisting of polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid, and polylactic-glycolic acid.
10. The liquid formulation according to claim 1 , wherein the pharmaceutically effective amount of the long-acting insulinotropic peptide conjugate has a concentration of about 0.5 mg/mL to about 150 mg/mL.
11. The liquid formulation according to claim 1 , wherein the pharmaceutically effective amount of the long-acting insulinotropic peptide conjugate has a concentration of about 4.0 mg/mL to about 50 mg/mL.
12. The liquid formulation according to claim 1 , wherein the sugar alcohol is one or more selected from the group consisting of mannitol, sorbitol, and sucrose.
13. The liquid formulation according to claim 12 , wherein a concentration of the sugar alcohol is about 3% (w/v) to about 15% (w/v) based on a total volume of the liquid formulation.
14. The liquid formulation according to claim 1 , wherein the buffer is a citrate buffer, an acetate buffer, or a histidine buffer.
15. The liquid formulation according to claim 1 , wherein the buffer is a citrate buffer.
16. The liquid formulation according to claim 15 , wherein a concentration of the citrate is about 10 mM to about 100 mM based on a total volume of the liquid formulation.
17. The liquid formulation according to claim 15 , wherein the citrate is present in a form of citric acid monohydrate.
18. The liquid formulation according to claim 1 , wherein the pH range of the formulation is about 5.2 to about 6.0.
19. The liquid formulation according to claim 1 , wherein the pH range of the formulation is about 5.4 to about 7.0.
20. The liquid formulation according to claim 1 , wherein the pH of the formulation is adjusted by using HCl and/or NaOH.
21. The liquid formulation according to claim 1 , wherein the non-ionic surfactant is polysorbate 80 or polysorbate 20.
22. The liquid formulation according to claim 1 , wherein the stabilizer further comprises methionine.
23. The liquid formulation according to claim 22 , wherein a concentration of the methionine is about 0.005% (w/v) to about 0.1% (w/v) based on a total volume of the liquid formulation.
24. The liquid formulation according to claim 1 , wherein the stabilizer further comprises one or more substances selected from the group consisting of a sugar, a polyalcohol, and an amino acid.
25. The liquid formulation according to claim 1 , further comprising one or more preservatives selected from the group consisting of m-cresol, phenol, and benzyl alcohol.
26. The liquid formulation according to claim 25 , wherein a concentration of the one or more preservatives is about 0.001% (w/v) to about 1% (w/v) based on a total volume of the liquid formulation.
27. The liquid formulation according to claim 25 , wherein the preservative is m-cresol.
28. A liquid formulation of a long-acting insulinotropic peptide conjugate, the liquid formulation comprising:
a pharmaceutically effective amount of the long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide is linked to an immunoglobulin Fc region via polyethylene glycol; and an albumin-free stabilizer, wherein the stabilizer comprises citrate buffer, mannitol, and polysorbate 20,
wherein,
the insulinotropic peptide is glucagon-like peptide-1, glucagon-like peptide-2, exendin-3, exendin-4, or imidazo-acetyl exendin-4;
the formulation has a pH of about 5.2 to about 7.0; and
the non-ionic surfactant has a concentration of about 0.001% (w/v) to about 0.05% (w/v).
29. The liquid formulation according to claim 28 , wherein the stabilizer further comprises methionine.
30. A liquid formulation of a long-acting insulinotropic peptide conjugate, comprising:
about 4 mg/mL, about 8.0 mg/mL, or about 12.0 mg/mL of the long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide is linked to an immunoglobulin Fc region via polyethylene glycol;
about 4.203 mg/mL citric acid monohydrate;
about 0.1 mg/mL L-methionine;
about 0.05 mg/mL polysorbate 20; and
about 40 mg/mL D-mannitol;
wherein
the formulation has a pH of about 5.6, and the pH of the formulation is adjusted by using NaOH; and the insulinotropic peptide is imidazo-acetyl exendin-4.
31. A multiple-use liquid formulation of a long-acting insulinotropic peptide conjugate, the multiple-use liquid formulation comprising:
a pharmaceutically effective amount of the long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide is linked to an immunoglobulin Fc region;
an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant; and
one or more preservatives selected from the group consisting of m-cresol, phenol, and benzyl alcohol,
wherein the insulinotropic peptide is glucagon-like peptide-1, glucagon-like peptide-2, exendin-3, exendin-4, or imidazo-acetyl exendin-4;
wherein the formulation has a pH of about 5.2 to about 7.0; and
wherein the non-ionic surfactant has a concentration of about 0.001% (w/v) to about 0.05% (w/v).
32. A method for preparing the liquid formulation of claim 1 , the method comprising:
mixing a long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide is linked to an immunoglobulin Fc region with a stabilizer comprising a buffer, a sugar alcohol, and a non-ionic surfactant;
wherein the insulinotropic peptide is glucagon-like peptide-1, glucagon-like peptide-2, exendin-3, exendin-4, or imidazo-acetyl exendin-4;
wherein the buffer has a pH of about 5.2 to about 7.0; and
wherein the non-ionic surfactant has a concentration of about 0.001% (w/v) to about 0.05% (w/v).
33. The method according to claim 32 , wherein the stabilizer further comprises methionine and/or a preservative.